Chongqing Taiji Industry (Group) Co., Ltd.

Taiji Group is a China-based pharmaceutical and TCM manufacturer headquartered in Chongqing. Founded in 1993 as the successor to a TCM factory established in 1972, the company is now a core subsidiary of state-owned Sinopharm Group. With 2025 revenue of CNY 10.5 billion, Taiji is the largest manufacturer of liquid TCM preparations in China, employing over 10,000 people across dozens of GMP-certified production facilities in southwestern China.

Core Business

Taiji specializes in Traditional Chinese Medicine oral liquids and syrups, with flagship products including Huoxiang Zhengqi Oral Liquid (a household name for heatstroke and gastrointestinal relief) and Jizhi Syrup (respiratory relief). The company also maintains substantial chemical pharmaceutical production capacity across cardiovascular, anti-infective, and parenteral nutrition segments. Its vertically integrated supply chain extends from herbal cultivation bases through extraction facilities to end-product distribution.

Key Strengths

1. The world's largest liquid TCM formulation capacity with annual output in billions of units. 2. Dramatic financial turnaround under Sinopharm integration — net profit surged 352.38% in 2025 with operating cash flow swinging from -CNY 631M to +CNY 584M. 3. Iconic OTC brands with multi-generational consumer trust across China and Southeast Asia. 4. Extensive GMP-certified factory network with heavy investment in automated filling and sterilization lines. 5. Vertically integrated operations from herbal cultivation to finished pharmaceutical distribution.

Challenges & Outlook

Despite dramatic profit recovery, top-line revenue contracted 15.23% in 2025 due to aggressive restructuring of its distribution network. The heavy reliance on seasonal product categories (heatstroke, cold/flu) introduces revenue volatility. Expanding beyond traditional Chinese and SE Asian markets remains a strategic challenge. VerityRank Score of 83/100 reflects strong manufacturing infrastructure and financial health recovery, moderated by revenue concentration risk.